Tagged with AstraZeneca,

Denmark Not only can Denmark lay claim to some major life science inventions – from the design of the world’s first ever insulin pen and disposable ostomy pouch to breakthroughs in fundamental discovery such as the development of the Gram Stain as an essential methodology for classifying bacteria – but it…

Denmark Despite its diminutive size, Denmark boasts a world-renowned healthcare and life science industry containing both household pharma giants as well as a robust network of academia, a host of niche service providers, and a growing throng of biotech start-ups. And with life science exports surpassing EUR 23 billion last year…

Alexion Dana Vigier, Regional Vice President at Alexion, AstraZeneca Rare Disease blends clinical training as a French general practitioner with broad pharmaceutical leadership experience. Formerly President of the French Pharma Association in Oncology and a Global Franchise leader at AstraZeneca, she now oversees Alexion’s operations across Central and Northern Europe, including…

Global The CGT field is undergoing a critical transformation from boom to thoughtful reset. While early enthusiasm brought a rush of investment and regulatory attention, the sector is now refining its ambitions, weeding out unviable approaches, and laying the foundations for long-term impact. Companies, regulators, and healthcare systems are rethinking what…

USA The latest stories from healthcare and the life sciences in the US. The FDA names Stanford’s George Tidmarsh as the new head of CDER; AstraZeneca commits USD 50 billion to new US manufacturing and R&D projects; Moderna cancels its planned mRNA facility in Japan; Sarepta refuses to halt Elevidys shipments…

UK The latest from UK pharma, including teething troubles and industry pushback for the country’s new life sciences strategy; Sanofi snapping up UK vaccines outfit Vicebio for USD 1.6 billion; and why AstraZeneca’s latest US manufacturing investment does little to ease fears that the British firm might choose to relocate across…

France France is experiencing its biggest pharmaceutical manufacturing boom in decades, with global giants like Novo Nordisk, Sanofi, and Pfizer committing over EUR 4 billion in new investments since 2023. This wave of capital represents more than just expansion – it signals a broader pivot toward European pharmaceutical independence and potentially…

Denmark Christof Bischoff, Country Director of AstraZeneca Denmark, draws on over two decades of international and national experience to navigate one of Europe’s most advanced yet complex healthcare environments. In this interview, he reflects on the affiliate’s evolution from a traditional commercial operation to a system-oriented partner driving innovation across clinical…

China A summary of top stories from China’s pharma industry: Sciwind Biosciences presents promising trial data for its obesity contender; Simcere reaches approval for its Idorsia-partnered insomnia therapy; AstraZeneca inks AI-enabled research deal with CSPC Pharmaceuticals, and the FDA blocks clinical trials that export American’s cells to China. Sciwind’s GLP‑1 data…

UK A roundup of the biggest UK pharma news, including the industry’s uncertain position after the UK-US trade accord; Haleon’s full takeover of its Chinese joint venture; AstraZeneca’s acquisition of Belgian biotech EsoBiotec and its exit from neuroscience; GSK’s liver disease asset deal with Boston Pharmaceuticals, and CellCentric’s US expansion.  …

Saudi Arabia Saudi Arabia’s pharmaceutical sector continues its impressive growth leadership within the region. With a 9.1 percent market growth in 2024 and a projected USD 11.6 billion in sales, the Kingdom now commands nearly a third of the entire MENA pharma market. But this story goes far beyond impressive numbers. Through…

Singapore Thanks to its strategic location and pro-business environment, Singapore has established itself as a major pharma manufacturing hub in the Asia-Pacific region. Five Big Pharma companies have stepped up their investments there as of late and either expanded existing manufacturing capabilities, or chosen the city-state as the location for a…